test

Developmental Therapeutics 

Gina G Chung MD

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

Breast Cancer


Board Certifications

 
Hematology, Board Eligible
2002
Medical Oncology, Board Certified

Patient Care Locations

 
gina_chungfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Breast - Female and Breast - Male Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Cancer, Breast - Female, and Breast - Male Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female and Breast - Male A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Breast - Female A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

Edit Profile